Pruritus · chronic pruritus of unknown origin
Serlopitant 5 mg may leads to higher patient‐reported pruritus intensity compared with placebo (low certainty).
1 finding from 1 review
Pruritus · chronic pruritus of unknown origin
Serlopitant 0.25 mg showed no clear difference in patient‐reported pruritus intensity compared with placebo (low certainty).
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · chronic pruritus of unknown origin
1 finding from 1 review
Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).
1 finding from 1 review
Depression · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · chronic pruritus of unknown origin
1 finding from 1 review
Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).
1 finding from 1 review
Depression · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · children with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
Physician‐assessed changes in clinical signs · children with eczema
1 finding from 1 review
Secondary outcome: quality of life · children with eczema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: clinical flare · children with eczema
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Minocycline 45 mg showed no clear difference in proportion of participants with adverse event compared with minocycline 45 mg + azelaic acid gel (low certainty).
1 finding from 1 review